Healthcare Industry News: embryonic stem cell
News Release - November 9, 2006
Advanced Cell Technology Names Current Chief Executive Officer William M. Caldwell IV as Chairman of the Board
ALAMEDA, Calif.--(HSMN NewsFeed)--Advanced Cell Technology, Inc. (OTCBB:ACTC ), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, today announced that current Chief Executive Officer, William M. Caldwell IV, has been appointed to serve as the Chairman of the Board in a unanimous vote by the company's directors.Mr. Caldwell will assume the role of Chairman from Dr. Michael D. West, who will continue in his role as President, Chief Scientific Officer and a director of Advanced Cell Technology. Dr. West, a recognized leader in the fields of embryonic stem cell science and regenerative medicine, will continue his focus on and commitment to ACTC's research and development programs.
"I want to thank Dr. West for his leadership at Advanced Cell Technology during his service as Chairman of the Board. We are all grateful for his current and continuing contributions," said Mr. Caldwell. "My role as CEO with ACTC's business and scientific teams has been extremely rewarding, and I welcome the Board's support in their decision to expand my duties to the position of Chairman."
About Advanced Cell Technology, Inc.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
For more information, please visit: www.advancedcell.com. For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/advanced_cell. To read or download Advanced Cell's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/advanced_cell/factsheet.html. To view recent stock quotes and news, visit http://www.trilogy-capital.com/tcp/advanced_cell/quote.html.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Source: Advanced Cell Technology
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
